International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL

Bruton’s tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options. However, since the approval of ibrutinib, concern has risen regarding the risk of cardiovascular (CV) adverse events,...

Descripción completa

Detalles Bibliográficos
Autores principales: Awan, Farrukh T., Addison, Daniel, Alfraih, Feras, Baratta, Sergio J., Campos, Rodrigo Noronha, Cugliari, María Silvana, Goh, Yeow Tee, Ionin, Valery Alexandrovich, Mundnich, Stefanie, Sverdlov, Aaron L., Tam, Constantine, Ysebaert, Loïc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631706/
https://www.ncbi.nlm.nih.gov/pubmed/35790105
http://dx.doi.org/10.1182/bloodadvances.2022007938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631706/
https://www.ncbi.nlm.nih.gov/pubmed/35790105
http://dx.doi.org/10.1182/bloodadvances.2022007938

Ejemplares similares